VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed advanced and/or metastatic solid tumor or lymphoma for which no curative or standard effective therapy exists
• •Measurable or evaluable metastatic disease
• •No other hematologic malignancy
• •No large pleural, pericardial, or peritoneal effusions
• •No requirement for immediate palliative treatment, including surgery
• •No symptomatic brain metastases or metastases with substantial edema
• •* Asymptomatic brain metastases or primary CNS disease allowed if neurologic deficits are stable
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-1
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •Granulocyte count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hematocrit at least 30% (transfusion allowed)
• •No active uncontrolled bleeding
• •Hepatic:
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• •ALT and AST no greater than 1.5 times ULN (3 times ULN if liver metastases present)
• •Alkaline phosphatase no greater than 1.5 times ULN (3 times ULN if liver or bone metastases present)
• •PT and aPTT no greater than 1.5 times ULN
• •Albumin at least 2.5 g/dL
• •Renal:
• •Creatinine no greater than 2.0 mg/dL
• •Cardiovascular:
• •Ejection fraction at least 45%
• •No active heart disease
• •No myocardial infarction within the past 3 months
• •No symptomatic coronary artery disease
• •No arrhythmias requiring medication
• •No uncontrolled congestive heart failure
• •Pulmonary:
• •DLCO and FEV\_1 at least 60% of predicted
• •No dyspnea with minimal to moderate exertion
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 3 months after study participation
• •HIV negative
• •No active infection
• •Persistent stable chronic toxic effects from prior therapy allowed if no greater than grade 1
• •No bleeding diathesis (e.g., active peptic ulcer disease)
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 3 weeks since prior biologic agents and recovered
• •At least 6 months since prior high-dose chemotherapy regimen with stem cell support
• •Chemotherapy:
• •See Biologic therapy
• •At least 3 weeks since prior cytotoxic agents (6 weeks for nitrosoureas or mitomycin) and recovered
• •Endocrine therapy:
• •At least 2 weeks since prior hormonal therapy and recovered
• •Radiotherapy:
• •At least 3 weeks since prior radiotherapy and recovered
• •Surgery:
• •See Disease Characteristics
• •At least 2 weeks since prior surgery and recovered
• •Other:
• •No other concurrent standard therapy for cancer
• •No other concurrent investigational agents
• •No concurrent disulfiram (Antabuse)